Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
Retrieved on:
Wednesday, September 6, 2023
Firefighter, DNA, Barrett's esophagus, Endoscopy, Partnership, International Association, Cancer, Woman, Market access, Attention, Government, San Antonio Fire Department, Lucid, NJ-5, Federal Fire Prevention and Control Act of 1974, Triage, Representative, Patient, Physician, Risk, Manuscript, SAFD, Esophageal cancer, National Association of Government Employees, Mesothelioma, Pleasure, Delaware Volunteer Firemen's Association, Mortality, MedRxiv, National Association, Louisiana House of Representatives, House, Legislation, Medical imaging, Nursing, Pharmaceutical industry
NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters.
Key Points:
- The release of these data closely aligns with and strongly supports recently proposed federal legislation seeking to fund guaranteed firefighter access to early detection tests such as EsoGuard.
- "Such clinical utility data, along with claims history, has been a key gating item for us to engage payors to secure in-network EsoGuard coverage.
- 391 SAFD fire fighters who were deemed by a physician to be at-risk for esophageal precancer participated in the event.
- EsoGuard provides an unprecedented precancer sensitivity of over 80 percent, while no other single or multi-cancer early detection test, blood-based or otherwise, provides any sensitivity in detecting esophageal precancer."